ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.
The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference.
Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.
Raj Chovatiya, MD, PhD, reviews a case of an adolescent patient with rapid changes in existing vitiligo.
A poster presented at the 2023 ReV Virtual Conference explored the association between the 2 conditions.
A poster from the 2023 Revolutionizing Atopic Dermatitis Conference revealed a link between AD, impaired oral health, and oral dysbiosis.
Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.
From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.
Christopher Bunick, MD, PhD, presented the research during a late-breaking research session during the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.
This week’s collection of the latest dermatologic studies covers skin cancer risk associated with phototherapy excluding psoralens, the role of the mycobiome in the development of atopic diseases, underrecognized pediatric vulvar diseases, and sunscreen deserts in Northeast, Ohio.
In January 2023, adalimumab-atto became the first biosimilar product available for the reference product adalimumab.
The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.
Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.
At the 2023 RAD Virtual Conference, Chovatiya presented a session titled, "Living the Cream."
Researchers have explored whether the adverse effects of tazarotene are exacerbated during the colder winter months and whether there is variation in treatment efficacy and tolerability between cold vs warm seasons.
One of the specific areas of focus will be non-melanoma skin cancer.
The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.
Study authors hypothesize that a monoclonal blockade of pathogenic T cells may induce expansion of regulatory immune cells subsets or expression of cytokines involved in skin homeostasis.
Lesional stability is a necessary requirement for determining the course of treatment for vitiligo.
52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.
Staying on top of products and ingredients patients are asking about is critical, especially this holiday season as they are considering gifts for loved ones.
Biolojic’s BD9 is a dual-specific antibody that can block both Thymic stromal lymphopoietin and IL-13.
David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.
The emergence of JAK inhibitors has shown tremendous promise as a novel therapeutic approach.
Catch up on coverage from this week's virtual Revolutionizing Atopic Dermatitis and Revolutionizing Vitiligo conferences.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.